🟢 Corcept Therapeutics is trading 12.39% up in pre-market ahead of November 3 Q3 results

Corcept Therapeutics is trading $91.17 (+12.39%) in pre-market amid anticipation of its November 3 Q3 results; no direct cause is confirmed.

• The company announced it will release results and provide a corporate update on November 3.
• A market report also linked momentum to positive October 26 Phase 2 BELLA trial results for Lifyorli, but did not confirm them as the cause.
• No reliable pre-market volume figure or confirmed new November 2 announcement was found.